---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056478"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:17:21.838352+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics Q3 loss widens to $30.7M; CFO and CMO depart; cash $320.9M

## Summary
- Q3 net loss $30.7M ($0.66/sh) vs $16.8M loss in Q3 2020; cash, equivalents and securities $320.9M.
- CFO Brian Piper resigns effective Nov 19; Laurent Chardonnet appointed CFO from Nov 29.
- CMO Dr. David Mauro mutually agreed to depart Nov 9; search for successor ongoing.
- PRT2527 IND cleared; Phase 1 trial to start by year-end; PRT543/811 expansion data expected in 2022.
- Retention bonus of $200k approved for EVP Deborah Morosini if employed through Nov 30, 2022.

## SEC filing metadata
- accession: 0001564590-21-056478
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000156459021056478/0001564590-21-056478-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000156459021056478/prld-8k_20211105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056478
- JSON: https://secwatch.observer/filing/0001564590-21-056478.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056478.txt

## Key facts
- Executive change
  Laurent Chardonnet was appointed as Chief Financial Officer at Prelude Therapeutics Inc.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On November 5, 2021, the Board of Directors of the Company (the “Board”) appointed Laurent Chardonnet as the Chief Financial Officer of the Company, including as the “principal financial officer” and “principal accounting officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective on or about November 29, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000156459021056478/0001564590-21-056478-index.htm
- Executive change
  Brian Piper resigned as Chief Financial Officer at Prelude Therapeutics Inc.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On November 5, 2021, Brian Piper, the Chief Financial Officer of the Company, notified the Company that he will be resigning from the Company, effective November 19, 2021, to pursue other opportunities.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000156459021056478/0001564590-21-056478-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.